drugset / Trial / NCT00656227

A Trial to Investigate Scar Improvement Efficacy of RN1001 (Avotermin) After Head and Neck Naevi Excision

NCT00656227

Phase 2 Unknown 239 enrolled Renovo
RandomizedFactorialTriple-blindPrevention

Summary

This trial will investigate whether four doses of RN1001 (20ng, 50ng, 100ng and 200ng) are efficacious in preventing or reducing the resultant scar, as compared to placebo, when applied intradermally to wound margins following excision of benign naevi situated on the head and neck.

Timeline

Start
2004-04
Primary completion
2007-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Avotermin Protein / enzyme biologic 20 ng Other
Subject Avotermin Protein / enzyme biologic 50 ng Other
Subject Avotermin Protein / enzyme biologic 100 ng Other
Subject Avotermin Protein / enzyme biologic 200 ng Other

Indications